# CANVAS - CANagliflozin cardioVascular Assessment Study

> **NCT01032629** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 4330 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Cardiovascular Diseases
- Risk Factors

## Interventions

- **DRUG:** Placebo
- **DRUG:** Canagliflozin (JNJ-28431754) 100 mg
- **DRUG:** Canagliflozin (JNJ-28431754) 300 mg

## Key facts

- **NCT ID:** NCT01032629
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-09
- **Primary completion:** 2017-02-22
- **Final completion:** 2017-02-22
- **Target enrollment:** 4330 (ACTUAL)
- **Last updated:** 2018-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01032629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01032629, "CANVAS - CANagliflozin cardioVascular Assessment Study". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01032629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*